Scarica l'app Stockscreener
27.00
1.24%
0.33
Pre-mercato:
27.20
0.20
+0.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$26.67
Aprire:
$26.69
Volume 24 ore:
42.45M
Relative Volume:
1.01
Capitalizzazione di mercato:
$153.59B
Reddito:
$62.58B
Utile/perdita netta:
$7.79B
Rapporto P/E:
19.92
EPS:
1.3551
Flusso di cassa netto:
$9.08B
1 W Prestazione:
-2.03%
1M Prestazione:
+0.15%
6M Prestazione:
+9.05%
1 anno Prestazione:
+18.53%
Intervallo 1D:
$26.58
$27.30
Intervallo di 1 settimana:
$26.38
$27.84
Portata 52W:
$21.97
$28.75
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.00 | 153.59B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors - TipRanks
Armata Pharmaceuticals adds Pfizer executive to board - Investing.com
Pfizer's (PFE) Zovegalisib Advances to Phase 3 for Breast Cancer Treatment - GuruFocus
Pfizer leader tied to Paxlovid launch joins Armata board - Stock Titan
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer - GlobeNewswire Inc.
Pfizer and 3 Other Stocks in Focus After Goldman Sachs and Others Buy and Sell Stakes - Trade Brains
Pfizer AGM: Shareholders Reject Independent Chair Proposal as Bourla Touts 2025 Gains and Pipeline - Yahoo Finance
Vanguard Group Inc. Raises Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by M&T Bank Corp - MarketBeat
Advisors Capital Management LLC Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Tests Transparent Eliquis Pricing As Valuation Signals Undervaluation - Yahoo Finance
There Are Early Signals Ahead of Tafamidis Trial As Analysts See Potential Upside for Pfizer (PFE) and BridgeBio Pharma (BIO) - Markets Herald
Pfizer (PFE) Quietly Reloads Pipeline With Bold New Bets - TipRanks
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know. - Yahoo Finance
Pfizer Eliquis Price Move With Cost Plus Raises Questions On Valuation - simplywall.st
Generali Investments Management Co LLC Purchases 65,552 Shares of Pfizer Inc. $PFE - MarketBeat
Calamos Advisors LLC Has $47.79 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer (NYSE:PFE) Shares Up 1.3%What's Next? - MarketBeat
Expanding Direct-To-Patient Options, BMS/Pfizer Add Eliquis To Cost Plus Drugs Portal - Citeline News & Insights
PFE Stock Quote Price and Forecast - CNN
Pfizer, Dexcel Drop Heart Drug Case Before Bench Trial - Law360
Is Pfizer’s Healthcare Reset Gaining Ground Through Obesity Care? - Kalkine Media
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - Seeking Alpha
Bristol Myers Squibb-Pfizer Alliance to sell Eliquis on Mark Cuban’s Cost Plus Drugs - ROI-NJ
Bristol Myers, Pfizer Bring Eliquis to Cost Plus at $345 Monthly - GuruFocus
Bristol Myers Squibb (BMY) and Pfizer (PFE) Launch Eliquis on Co - GuruFocus
Pfizer Plans To Challenge $9.1M Tax Bill In India - Law360
Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story. - Barchart
Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners - Insider Monkey
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy - Reuters
Pfizer presents auristatin S ADC for GPNMB tumors - BioWorld News
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company - marketscreener.com
Pfizer Obesity Pipeline Expands As Monthly GLP 1 Candidate Targets Growth - simplywall.st
Pfizer Ltd Receives Tax Demand Of 857.4 Million Rupees - TradingView
Ahead of NFL Draft night, Fernando Mendoza signs with Pfizer - Medical Marketing and Media
Pfizer stock drops 1.57% as AI accelerates cancer research participation and discovery - Traders Union
Pfizer : Announces 2026 Shareholder Meeting Preliminary ResultsCorporateFinance - marketscreener.com
Pfizer Advances PF-08653944 Liver Study, Reinforcing Long-Term Pipeline Visibility - TipRanks
Pfizer’s New Phase 1 Cancer Trial Adds Quiet Optionality to PFE’s Pipeline - TipRanks
Albert Bourla: Pharmaceutical Visionary, COVID-19 Vaccine Champion, and Chairman and CEO of Pfizer - BBN Times
Torray Investment Partners LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Mystic Asset Management Inc. - MarketBeat
Pfizer Inc. to Issue Quarterly Dividend of $0.43 (NYSE:PFE) - MarketBeat
The Escalator: Pfizer, Eton Pharmaceuticals, Steak ‘n Shake and more - Medical Marketing and Media
PFE (Pfizer Inc.) posts 14.3 percent Q4 2025 EPS beat, stock rises 1.25 percent in regular trading.Community Exit Signals - UBND thành phố Hải Phòng
Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Pfizer declares $0.43 dividend - MSN
Pfizer declares $0.43 quarterly dividend payable in June By Investing.com - Investing.com India
Pfizer To Go Ex-Dividend On May 8th, 2026 With 0.43 USD Dividend Per Share - Moomoo
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.42%
6.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):